Current and Emerging Therapeutics in Cystic Fibrosis: Ensuring Continuity of Care within the New Treatment Paradigm

This activity is supported by an educational grant from Vertex Pharmaceuticals, Inc.

Current and Emerging Therapeutics in Cystic Fibrosis: Ensuring Continuity of Care within the New Treatment Paradigm

Faculty

Robert J. Kuhn, BS, PharmD

Kentucky Hospital Association Endowed Professor

Department of Pharmacy Practice and Science

University of Kentucky College of Pharmacy

Lexington, Kentucky

Elizabeth Autry, PharmD

Pediatric Clinical Pharmacist

Pediatric Pulmonary and Endocrinology

Specialty Pharmacy Services

University of Kentucky HealthCare

Lexington, Kentucky

Educational Objectives

After completing this continuing education program, the participant will be able to:

• Apply knowledge of the changing face of cystic fibrosis (CF), in terms of microbiology and patient demographics, to optimize treatment efficacy, treatment adherence, and overall management of CF
• Illustrate the pathobiology and pathogenesis of CF and the role of existing therapeutics
• Examine the importance of airway clearance and the continued role of chronic suppressive antibiotic therapy in treatment of pulmonary exacerbations
• Analyze the latest clinical data on agents targeting various mutations in CF
• Explore the potential impact of clinical advances in CF on multimodal treatment options and strategies, and communicate effectively with patients and their families about the role of genetic analyses

Target audience:

Specialty, ambulatory

care, and community retail pharmacists

Type of activity: Application

Release date: December 7, 2015

Expiration date: December 7, 2016

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-15-154-H01-P. The activity is available for CE credit through December 7, 2016.